Nuvectis Pharma, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Nuvectis Pharma, Inc. (NVCT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 5.01 million shares for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-08.
Discontinued › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2023-03-08
- Nuvectis Pharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 5.01M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|
| 2021-12-31 | 5.01M shares 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |